Sun Pharma CHC Forays into Anti-fungal Powder OTC Category with ABZORB | CORPORATE ETHOS

Sun Pharma CHC Forays into Anti-fungal Powder OTC Category with ABZORB

By: | April 30, 2018
sun pharma

Apr 30: Sun Pharma Consumer Healthcare (CHC), a division of drug making major Sun Pharmaceutical Industries Ltd, HAS announced its entry into the anti-fungal powder OTC category with ABZORB.

According to the company, the brand will be co-promoted across prescription & OTC channels in India to drive growth. Sun Pharma CHC has launched a 360° marketing campaign comprising TV, print & digital to expand consumer outreach, it said.

“ABZORB’s unique combination of talc AND starch ensures superior sweat absorption and clotrimazole, one of the best-in-class anti-fungal, helps treat infection & prevents its recurrence. The product is available in 100 g & 50 g packaging,” the company added.

Commenting on the development, Vidhi Salgaocar, Head, Consumer Healthcare, Sun Pharma said, “we are excited to offer consumers the Brand of Choice by dermatologists – ABZORB. Fungal infections are a common occurrence and are often left untreated because of the associated social stigma. The intent of the 360° marketing campaign is to raise consumer awareness regarding fungal infections and empower them to treat the infection and lead a healthier life.”

According to Sun Pharma, the anti-fungal powder category is estimated to be over Rs 100 crore in India (IMS MAT August 2017) and ABZORB is a key player in the segment. Inconsistent weather conditions with increasing instances of high temperatures and unexpected rain has increased the incidence of fungal infections, with the category growing at over 15% every year, it said.

Shares of Sun Pharmaceutical Industries closed trading at Rs 528.15, up 0.74% from the previous closing of Rs 524.25, on BSE today.